Monday, February 24, 2020 Daily Archives

Repligen up on OPUS and gene therapy demand

by

Repligen says it will continue to expand capacity to feed demand for its OPUS range of prepacked chromatography columns. For the full year 2019, revenues at bioprocess vendor Repligen Corporation came in at $270 million (€250 million), up from $194 million in 2018. Revenues grew across all the firm’s divisions, with organic growth of 20%, 30% and 40% for Repligen’s proteins, filtration and chromatography franchises, respectively. And within the chromatography franchise, the firm’s OPUS range of prepacked chromatography columns stood…

February 24, 2020

AveXis ‘flexible’ NC plant a step closer to fully internal gene therapy network

by and

AveXis has opened a gene therapy plant in Durham it says will be able to produce up to seven products simultaneously. President Dave Lennon talks timelines, capacity, and taking production inhouse. AveXis and its owner Novartis have invested a total of $115 million (€106 million) into a site in Durham, North Carolina to support the production of US Food and Drug Administration (FDA) approved product Zolgensma (onasemnogene abeparvovec) and its pipeline of gene therapy candidates. With the doors opening last…

February 24, 2020